Air National Guard



LARGE-SCALE LACTATE INJECTION IN A MILDLY-REDUCING AQUIFER FOR PCE/TCE DECHLORINATION


James R. Romer (james.r.romer@saic.com), Ken Swain (SAIC, Oak Ridge, TN, USA) Kent S. Sorenson, Jennifer P. Martin (North Wind, Inc., Idaho Falls, ID, USA) Lisa Alvarez-Cohen (University of California, Berkeley, CA, USA) Badrul-Hoda, and Cpt. David L. Kellner (Air National Guard)





164th Airlift Wing ANG, Memphis International Airport

Bounded to the West and North by Memphis International Airport



Bounded to the South and East by Federal Express





TCE Concentrations In Groundwater








PROJECT OBJECTIVES

- To provide low cost, low maintenance reduction in chlorinated solvents at the source
- To provide supplemental data through the pilot study for inclusion in the FS currently being conducted












Specifications

Specification	Typical	
Sodium Lactate, % by wt.	60 ± 1.2	60 ± 0.5
H ₂ O	40 ± 1.2	40 ± 0.5
рН	70 ± 0.5	6.8 - 7.2
Color, APHA	25 max	10
Iron, ppm	2 max	<5
Heavy Metals, ppm	10 max	<1
Specific Gravity	1.3100-1.3400	
Specific Gravity of Injected Material (4%) 1.02		
Chloride, ppm	500 max	
Citrate, Oxalate,		
Phosphate, Tartrate	none detected	
Sulfate	none detected	
Sugars	none detected	
Methanol, Methyl Esters (ppm)	250 max	
Sodium, %	12.3 ± 0.2	
Odor	Practically odorless	





Optimized Well Locations With 3-D Model







Pull-Technique HDPE Burial







Pull-Technique HDPE Burial







Heat Fusion Coupling








Na Lactate Drop Tube







Potable Water Source







Mixers for Homogenous 1% Solution







Distribution Header For Optimal System Control







Food-grade Na Lactate







First Injection

- Confirmation of mixing
- Calibration of pumping rates for each well
- Monitoring of Mounding
 - Injection wells (9 to 19 ft) 38 ft
 - Monitoring wells (0.75 to 6.25 ft)





Anticipated Schedule

- First injection May, 2002
- Post completion technical memorandum June 20, 2002
- Second injection July, 2002
- Third injection September, 2002
- Fourth injection November, 2002
- Post-treatment sampling-January, 2003
- Follow up sampling March, 2003
- End of 1-yr pilot study May, 2003
- End of year report June, 2003
- *Pre-injection sampling will be conducted 1wk prior to each injection






System Monitoring Sampling

- 9 injection wells and 6 monitoring wells sampled (2 additional MW side- and downgradient for Sept. sampling)
- Distribution, Chemical Reduction, & Redox
- Analyses
 - Field measured
 - Ferrous Iron, alkalinity, temperature, pH, specific conductance, diss. oxygen, oxidation reduction potential
 - Laboratory
 - Chlorinated ethenes, ethene/ethane/methane, chemical oxygen demand, lactate, acetate/propionate/butyrate, sulfate, phosphate, ammonia as nitrogen, carbon dioxide






COD Distribution








Redox Conditions








Redox Conditions, March 2003








Analytical Results for Monitoring Wells Outside the Target Treatment Area








Molar Concentrations in System Monitoring Wells








Molar Concentrations from Pre-injection Hot Spots in the Shallow and Deep Portions of the Water Table Aquifer








VOCs in IW-5 (a) and 03-020mw (b)







Injection Area TCE Concentrations >500 ug/L



Conclusions

Nine months of monitoring during lactate injection in a large-scale mildly reducing aquifer indicate that

- The injection system successfully delivered significant quantities of an electron donor throughout the treatment area.
- Methanogenic conditions were achieved throughout the treatment area.
- Stoichiometric ARD to *cis*-DCE was observed throughout the treatment area.
- Baseline DNA screening indicated the absence of DHE in site groundwater prior to electron donor injection.
- The absence of advanced ARD beyond *cis*-DCE may be a result of insufficient time for biomass growth, or may be due to the absence of the organisms required for advanced ARD. Future activities include continued monitoring (including DHE monitoring) to determine if bioaugmentation is required in order to achieve complete ARD to ethene.



